AlloHCT With PegINFa for Myelofibrosis
Key claim: A Phase 1 dose de-escalation study is evaluating the safety and recommended phase 2 dose of pegylated interferon alfa-2a administered after allogeneic hematopoietic cell transplantation in patients with primary or secondary myelofibrosis.
Abstract
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Why this matters
Post-alloHCT maintenance is an increasingly active execution-layer question in MF, where relapse remains a dominant cause of transplant failure but options are limited. Pegylated interferon alfa-2a — long established in non-transplant MPN management for its disease-modifying and allele-burden-reducing effects — has not previously been formally tested as post-transplant maintenance, making this Phase 1 a first-in-class extension of a familiar MPN drug into the peri-transplant space. It does not change who should be transplanted or when, but expands the post-transplant toolkit alongside HMAs and emerging cellular therapies.